Investigators reviewed ocular side effects of semaglutide use from a global population-based study across 180 countries.

In this episode, host Tylah Tully unpacks the latest news from Orthocell (ASX:OCC), who has raised $30 million to accelerate global commercialisation of its flagship nerve-repair product Remplir. The ...

(MENAFN- EIN Presswire) EINPresswire/ -- Optic neuropathies including glaucoma, traumatic injury, ischemic damage, and optic neuritis, are the leading causes of irreversible blindness worldwide; ...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully unpacks the latest news from Orthocell (ASX:OCC), who has raised $30 million to ...

Detailed price information for Nurexone Biologic Inc (NRX-X) from The Globe and Mail including charting and trades.

1 Clinical Medical College of North Sichuan Medical College, Nanchong, Sichuan, China 2 Department of Anesthesiology, Guang'an People's Hospital, Guang'an, Sichuan, China Arthroscopic rotator cuff ...

Summary: Researchers have identified two compounds capable of repairing the protective myelin sheath damaged by multiple sclerosis, a major advance toward reversing nerve injury rather than just ...

TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone ” or the “Company ”) a ...

ROCKY MOUNT, N.C. (WNCN) — North Carolina authorities said last week they busted a father and son who were running a drug business out of an auto repair shop. The six-month investigation focused on ...

ROCKY MOUNT, N.C. (WNCN) — Police in Rocky Mount said last week they busted a father and son who were running a drug business out of an auto repair shop. The six-month investigation focused on ...

The combination of task-oriented training and vagus nerve stimulation has recently received Food and Drug Administration approval to improve upper limb recovery in individuals with chronic stroke.

Oculis is advancing privosegtor into registrational trials for neuro-ophthalmology indications, including AON and NAION, following FDA guidance. The PIONEER program will consist of 3 pivotal trials, ...